NewsBenzingaRapport Therapeutics inicia ofertas públicas suscritas separadas de acciones por 200 millones de dólares y de bonos senior convertibles por un importe principal agregado de 150 millones de dólares con vencimiento en 2032 Rapport Therapeutics inicia ofertas públicas suscritas separadas de acciones por 200 millones de dólares y de bonos senior convertibles por un importe principal agregado de 150 millones de dólares con vencimiento en 2032 Benzinga 2026.10.27 20:35 (GMT+0) Open on Benzinga Other news Bernie Sanders Sounds Alarm On US Affordability Crisis, Says 60% of Americans Live Paycheck to Paycheck: 'Wall Street and the Billionaire Class…' Salesforce Issues Security Advisory On Third-Party Optimizely Script Incident Affecting Certain Salesforce-Branded Sites; Optimizely Scripts Being Confirmed Disabled FBI Reissues Warning About AI-Powered Cyberattacks on Businesses as Crypto Bettors Dismiss AI Link to FAA Outage SpaceX, Meta and Nebius Stand to Benefit From Nvidia’s ‘Fastest Product Ramp’ Yet: Strategist Shay Boloor Explains Why Innate Pharma Reports IPH4502 Phase 1 Data Across 76 Patients: Maximum Tolerated Dose 3.6 Mg/Kg Q3W, Grade 3+ TEAEs In 43.4%, Stomatitis Only Dose-Limiting Toxicity Olema Reports Selective KAT6A Degraders Potently Inhibit Proliferation In Diverse ER+/HER2- Breast Cancer Models, Active In ESR1-Mutant And Wild-Type, Well-Tolerated
Bernie Sanders Sounds Alarm On US Affordability Crisis, Says 60% of Americans Live Paycheck to Paycheck: 'Wall Street and the Billionaire Class…'
Salesforce Issues Security Advisory On Third-Party Optimizely Script Incident Affecting Certain Salesforce-Branded Sites; Optimizely Scripts Being Confirmed Disabled
FBI Reissues Warning About AI-Powered Cyberattacks on Businesses as Crypto Bettors Dismiss AI Link to FAA Outage
SpaceX, Meta and Nebius Stand to Benefit From Nvidia’s ‘Fastest Product Ramp’ Yet: Strategist Shay Boloor Explains Why
Innate Pharma Reports IPH4502 Phase 1 Data Across 76 Patients: Maximum Tolerated Dose 3.6 Mg/Kg Q3W, Grade 3+ TEAEs In 43.4%, Stomatitis Only Dose-Limiting Toxicity
Olema Reports Selective KAT6A Degraders Potently Inhibit Proliferation In Diverse ER+/HER2- Breast Cancer Models, Active In ESR1-Mutant And Wild-Type, Well-Tolerated